The success of the EGFR and VEGFR pathway antagonists in treatment of metastatic NSCLC has important implications for development of novel targeted therapies such as the PKC inhibitors.

The process identified in this study could offer a promising target for the development of new treatments to prevent the further spread of metastatic cancer.